NCT03926286 is a Phase 1 clinical trial of FMP-30 in Sjogren's Syndrome, sponsored by University of Miami.

Who is sponsoring NCT03926286?

NCT03926286 is sponsored by University of Miami.

What drugs are being tested in NCT03926286?

Interventions in NCT03926286: FMP-30.

What condition does NCT03926286 study?

NCT03926286 studies Sjogren's Syndrome.

Is NCT03926286 still recruiting?

NCT03926286 is currently completed. Last updated 5 June 2020.

Last reviewed 2020-06-05 · How we verify

NCT03926286

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fecal Microbial Transplant (FMT) for Sjogrens Syndrome

Completed Phase 1 Last updated 5 June 2020

What this trial tests

Phase 1 trial testing FMP-30 in Sjogren's Syndrome in 10 participants. Completed in 1 June 2020.

Timeline

15 April 2019

Primary endpoint
1 June 2020

1 June 2020

Quick facts

Lead sponsor	University of Miami
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	15 April 2019
Primary completion	1 June 2020
Estimated completion	1 June 2020
Sites	1 location across United States

Drugs / interventions tested

FMP-30 — full drug profile →

Conditions studied

Sjogren's Syndrome — all drugs for Sjogren's Syndrome →

Sponsor

University of Miami

Who can join

18 and older, any sex, with Sjogren's Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open label study to evaluate the effect of Fecal Microbiota Transplantation (FMT) on the gut microbiome and Systemic parameters.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Relationships Between Vitamin D, Gut Microbiome, and Systemic Autoimmunity.
Yamamoto EA, Jørgensen TN. · · 2019 · cited 151× · PMID 32038645 · DOI 10.3389/fimmu.2019.03141
Fecal microbiota transplantation beyond Clostridioides difficile infections.
Wortelboer K, Nieuwdorp M, Herrema H. · · 2019 · cited 111× · PMID 31201141 · DOI 10.1016/j.ebiom.2019.05.066
The gut-eye-lacrimal gland-microbiome axis in Sjögren Syndrome.
Trujillo-Vargas CM, Schaefer L, Alam J, Pflugfelder SC, et al · · 2020 · cited 71× · PMID 31644955 · DOI 10.1016/j.jtos.2019.10.006
Gut Dysbiosis and Fecal Microbiota Transplantation in Autoimmune Diseases.
Belvoncikova P, Maronek M, Gardlik R. · · 2022 · cited 61× · PMID 36142642 · DOI 10.3390/ijms231810729
Autoimmunity in dry eye disease - An updated review of evidence on effector and memory Th17 cells in disease pathogenicity.
Chen Y, Dana R. · · 2021 · cited 55× · PMID 34509656 · DOI 10.1016/j.autrev.2021.102933
Dry eye syndrome: comprehensive etiologies and recent clinical trials.
Huang R, Su C, Fang L, Lu J, et al · · 2022 · cited 52× · PMID 35678897 · DOI 10.1007/s10792-022-02320-7
Fecal Microbial Transplant in Individuals With Immune-Mediated Dry Eye.
Watane A, Cavuoto KM, Rojas M, Dermer H, et al · · 2022 · cited 49× · PMID 34214453 · DOI 10.1016/j.ajo.2021.06.022
The role of the microbiome in gastrointestinal inflammation.
Sanders DJ, Inniss S, Sebepos-Rogers G, Rahman FZ, et al · · 2021 · cited 41× · PMID 34076695 · DOI 10.1042/bsr20203850

Verify or expand the search:

Other recruiting trials for Sjogren's Syndrome

Currently open trials in the same condition.

NCT07281456 — Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease · Phase 2 · recruiting
NCT07180537 — Creating Health Course Study for People With Rheumatological Conditions · NA · recruiting
NCT07236762 — An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases · Phase 1 · recruiting
NCT07041099 — A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease · Phase 1 · recruiting
NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting

Other University of Miami trials

Trials by the same sponsor.

NCT06003712 — Exploring the Effect of Mindfulness on Quality of Life (QoL) in Spinal Cord Injury (SCI) · NA · not yet recruiting
NCT06077071 — MRIdian "RADAR" Trial · NA · not yet recruiting
NCT07472413 — Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project · Phase 3 · not yet recruiting
NCT07322289 — Antibiotic-coated Braided Suture Study · NA · not yet recruiting
NCT07469592 — eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03926286 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Miami
Last refreshed: 5 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03926286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing